araag2/HINT huggingface dataset:
Clinical trial NCT01097512 (phase 1, status: completed)
Conditions: pancreatic cancer
ICD codes: C25.3
Drugs: as703569/gemcitabine, as703569/gemcitabine
SMILES: [H][C@@]12C[C@@]([H])(C=C1)[C@@H]([C@@H]2NC1=C(F)C=NC(NC2=CC=C(N3CCN(C)CC3)C(C)=C2)=N1)C(N)=O, [H][C@@]12C[C@@]([H])(C=C1)[C@@H]([C@@H]2NC1=C(F)C=NC(NC2=CC=C(N3CCN(C)CC3)C(C)=C2)=N1)C(N)=O
Eligibility criteria:

        Inclusion Criteria:

        Histologically/cytologically confirmed diagnosis of measurable or assessable malignancy,
        who meets one of the following conditions:

        Subject with a tumour for which gemcitabine is approved, Subject with a tumour for which
        gemcitabine is considered standard of care, Subject with other tumour type either
        refractory or intolerant to or for whom there is not an accepted standard treatment.

        Male or female with at least 18 years of age. Life expectancy of at least 3 months.

        Eastern Cooperative Oncology Group (ECOG) Performance Status < 2.

        No more than 3 prior chemotherapy regimens for advanced/metastatic disease.

        At least 4 weeks since last chemotherapy, hormonal therapy, immunotherapy, biological or
        any other pharmacological or investigational treatment or radiotherapy (6 weeks wash-out
        for nitrosoureas and mitomycin C, 5 half-lives for non-cytotoxics). Subjects on chronic
        hormonal therapy may continue with the same treatment unchanged.

        Adequate renal, hepatic and bone marrow functions (assessed 7 days before inclusion in the
        trial) as defined by:

        Serum creatinine
Clinical trial NCT01130376 (phase 1, status: terminated)
Conditions: hiv-1 infection
ICD codes: B20, Z71.7, O98.72, Z21, O98.73, R75, Z11.4
Drugs: interleukin-2, gm-csf, growth hormone
SMILES: COCCC1=CC=C(OCC(O)CNC(C)C)C=C1
Reason stopped: 
    data from the 12 patients recruited has now been analysed, and it has been determined that it
    is sufficient to meet the study objectives.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Documented HIV-1 positive result.

          -  Stable on HAART.

          -  Two screening viral loads of <50 cps/ml on 2 consecutive occasions at least one month
             apart.

          -  CD4 T cell count of >400 cells/ul.

          -  Nadir CD4 T cell count of >200 cells/ul.

          -  Over 18 years of age.

          -  Willing and able to provide informed consent.

          -  Female subjects must not be pregnant or lactating.

          -  Subjects must be using adequate double barrier method of contraception as appropriate.

        Exclusion Criteria:

          -  Prior therapeutic vaccination.

          -  Acute illness within 2 weeks of the start of the study.

          -  Prior immunomodulatory therapy (e.g. IL-2, rhGH, GCSF, GM-CSF, HU)

          -  Receiving immunosuppressive medication (e.g. Steroids)

          -  Participation in other vaccine trials currently

          -  Patients with diabetes mellitus type 2

          -  Patients with cardiac abnormalities

          -  Patients with pre-existing autoimmune disease

          -  Patients with active neoplasia

          -  Patients with evidence of any progression or recurrence of an underlying intra-cranial
             lesion
Clinical trial NCT00420407 (early phase 1, status: terminated)
Conditions: injuries, shock, traumatic
ICD codes: P15.8, T07.XXXS, P12.89, P13.1, P14.3, T07.XXXA, T07.XXXD, T79.4XXS, T79.4XXA, T79.4XXD
Drugs: normal saline control, vasopressin
SMILES: CC1=CC(O)=CC(C)=C1Cl, N[C@@H](CCCNC(N)=N)C(O)=O
Reason stopped: 
    accrual rate
  
Eligibility criteria:

        Inclusion Criteria:

        To be eligible for enrollment in the study, a patient must meet all of the follow criteria
        at assessment:

          -  Patient is a male or female patient presumed to be at least 18 years of age;

          -  Patient has a systolic blood pressure < 90 mmHg;

          -  Patient has clinical evidence of acute traumatic injury;

          -  Infusion of study drug must start within one hour following SBP (systolic blood
             pressure) < 90 mmHg

        Exclusion Criteria:

        A patient meeting any one of the following criteria at hospital assessment is not eligible
        for enrollment:

          -  Patient is admitted to one of the study hospitals' Emergency Department greater than
             six hours after injury;

          -  Patient has received greater than 4 liters fluid since time of injury;

          -  Patient is enrolled in another shock trial;

          -  Patient is asystolic or requires CPR (cardiopulmonary resucitation) prior to
             randomization;

          -  Female patient is pregnant by report or suspicion;

          -  Patient has known "Do Not Resuscitate" orders or visible/identifiable method of
             objection to participation (e.g., exclusion bracelet);
Clinical trial NCT00304525 (phase 1/phase 2, status: completed)
Conditions: metastatic melanoma
ICD codes: C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4
Drugs: raf265
SMILES: CN1C(NC2=CC=C(C=C2)C(F)(F)F)=NC2=CC(OC3=CC=NC(=C3)C3=NC=C(N3)C(F)(F)F)=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          1. Confirmed diagnosis of melanoma, locally advanced AJCC Stage IIIB to metastatic Stage
             IV

          2. Measurable disease - at least one lesion measured in at least one dimension as ≥ 20 mm
             with conventional techniques or ≥ 10 mm with spiral computed tomography (CT) scan

          3. ECOG performance status of 0 or 1

          4. No concurrent anticancer or investigational therapy for at least 4 weeks prior to
             enrollment

          5. No major surgery for at least 4 weeks prior to enrollment

        Exclusion Criteria:

          1. Significant cardiac disease or other significant medical/psychiatric disease

          2. History of primary central nervous system tumor or brain metastases

          3. History of melena, hematemesis, or hemoptysis within the last 3 months

          4. Previous therapy with certain molecularly targeted agents
Clinical trial NCT00036634 (phase 1/phase 2, status: completed)
Conditions: hiv infections
ICD codes: Z21
Drugs: tenofovir df, tenofovir alafenamide
SMILES: [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C, CC(C)OC(=O)[C@H](C)N[P@](=O)(CO[C@H](C)CN1C=NC2=C(N)N=CN=C12)OC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria

          -  HIV-1 RNA levels greater than or equal to 30,000 copies/mL

          -  CD4 count greater than or equal to 200 cells/mm3

          -  Serum creatinine <1.5 mg/dl

          -  Hepatic transaminases less than or equal to 2.5 times the upper limit of normal

          -  Total bilirubin less than or equal to 1.5 mg/dL

          -  Adequate hematologic function

          -  Serum amylase less than or equal to 1.5 times the upper limit of normal

          -  Serum phosphate greater than or equal to 2.2 mg/dL

          -  Not pregnant

        Exclusion Criteria

          -  Prior treatment with antiretroviral therapy

          -  Immunization within 30 days of study entry

          -  A new AIDS defining condition within 30 days of study entry

          -  Receiving nephrotoxic agents, probenecid, chemotherapeutic agents, corticosteroids,
             interleukin-2
Clinical trial NCT00302744 (phase 1, status: completed)
Conditions: anxiety
ICD codes: F41.1, F41.9, F40.8, F40.9, F41.3, F41.8, F43.22
Drugs: psilocybin (drug)
SMILES: CN(C)CCC1=CNC2=CC=CC(OP(O)(O)=O)=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Have advanced-stage cancer and anxiety.

          -  Be between the ages of 18 - 70.

        Note: The location for the two treatment sessions is Los Angeles, California. Treatment
        sessions are scheduled three to six weeks apart, and they include one overnight hospital
        stay both times.

        Exclusion Criteria:

          -  Not have cancer that affects the central nervous system or brain function.

          -  Have no history of major psychiatric disorder.

          -  Have no kidney disease, abnormal liver functions, epilepsy, or cardiovascular disease,
             including untreated hypertension.

          -  Not be taking insulin, oral hypoglycemic, anti-seizure, or cardiovascular medications
             (except anti-hypertensive drugs).

          -  May take PRN benzodiazepines up to 3 days before the session.

          -  No Prozac for the previous 5 weeks.

          -  No medications the day of and the day after treatment sessions, except may take
             ongoing adjuvant chemotherapy as prescribed, prescribed or over-the-counter
             non-narcotic pain medication at any time, and narcotic pain medications up to eight
             hours before administration of psilocybin and six hours after administration.

          -  No alcohol consumption the day before, the day of, and the day after a session.

          -  Female subjects of childbearing potential must have a negative pregnancy test and
             agree to use an effective form of birth control.
Clinical trial NCT00473512 (phase 1/phase 2, status: completed)
Conditions: prostatic neoplasms
ICD codes: B38.81, N42.31, Z87.430, N40.0, N40.1
Drugs: abiraterone acetate, abiraterone acetate mtd, dexamethasone
SMILES: [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically (pertaining to the disease status of body tissues or cells) documented
             adenocarcinoma of the prostate, clinically refractory (not responding to treatment) or
             resistant to hormone therapy, as documented by progression following at least one
             hormonal therapy

          -  Prostate specific antigen (PSA) evidence for progressive prostate cancer

          -  Participants who were withdrawn from anti-androgen therapy less than 6 months prior to
             inclusion in the study require one PSA higher than the last pre-withdrawal PSA or 2
             increases in PSA documented after the post-withdrawal nadir(value) greater than or
             equal to 4 weeks from treatment withdrawal if treated with flutamide and greater than
             or equal to 6 weeks if treated with bicalutamide or nilutamide

          -  Eastern Cooperative Oncology Group (ECOG) performance status score equal to 0 or 1

          -  Life expectancy of greater than or equal to12 week

        Exclusion Criteria:

          -  Participants with central nervous system (the brain and spinal cord) disease and/or
             brain metastases

          -  No currently active second malignancy (cancer or other progressively enlarging and
             spreading tumor) other than non-melanoma skin cancer

          -  Myocardial infarction within the 6 months prior to start of study

          -  No active or uncontrolled autoimmune disease (disorder in which a person's immune
             system attacks parts of his or her own body) that may require corticosteroid therapy
             during protocol treatment

          -  Major surgery or significant traumatic injury within 4 weeks of start of study
Clinical trial NCT00397293 (phase 1/phase 2, status: completed)
Conditions: small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: at-101, topotecan
SMILES: [H][C@]1(O)CO[C@]2([H])[C@]([H])(O)CO[C@]12[H], CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed small cell lung cancer (SCLC). Mixed
             histology will not be eligible.

          -  Progression of disease after only one prior platinum containing chemotherapy regimen.
             Prior Regimen must not have contained irinotecan

          -  All patients must have measurable disease.

          -  Patients may have received prior radiation therapy but they must have recovered from
             all treatment-related toxicities.

          -  ECOG performance status 0-1

          -  Adequate hematologic function

          -  Adequate liver and renal function

          -  Ability to swallow oral medication

        Exclusion Criteria:

          -  Patients with more than one prior regimen of chemotherapy or prior regimen that did
             not contain a platinum agent. Note: Patient who stopped prior therapy due to toxicity
             or had less than 2 cycles of platinum based therapy would not be eligible for the
             phase II portion of this study.

          -  Prior chemotherapy regimen containing irinotecan.

          -  Active secondary malignancy.

          -  Unstable or progressive brain metastases.

          -  Prior history of radiation therapy to > 25% of the bone marrow.

          -  Uncontrolled concurrent illness including, but not limited to: serious uncontrolled
             infection, symptomatic congestive heart failure (CHF), unstable angina pectoris,
             cardiac arrhythmia, or psychiatric illness/social situations that would limit
             compliance with the study requirements.

          -  Failure to recover from toxicities related to prior therapy (e.g., surgery, radiation,
             chemotherapy).
Clinical trial NCT01471548 (phase 1, status: completed)
Conditions: advanced solid tumors
ICD codes: K74.02, G47.22, H35.3133, H35.3134, H35.3113, H35.3114, H35.3123
Drugs: tki258
SMILES: CN1CCN(CC1)C1=CC=C2N=C(NC2=C1)C1=C(N)C2=C(NC1=O)C=CC=C2F
Eligibility criteria:

        Inclusion Criteria:

          -  Written informed consent must be obtained prior to any screening procedures

          -  Advanced solid tumors

          -  Agreement to remaining hospitalized

          -  ECOG performance status of 0 or 1

          -  Life expectancy of at least 3 months

          -  Pregnant women. Male and female patients of reproductive potential must agree to
             employ an effective method of birth control

          -  Demonstrate the specific hematological /blood chemistry laboratory values

        Exclusion Criteria:

          -  Receipt of any investigational compound within 28 days prior to the first dose of
             study drug or failure to have recovered from the side effects of such prior therapy

          -  Receipt of other antineoplastic therapy, including chemo-, hormonal, immuno-, and
             radiation therapy, within 28 days (with some exceptions)

          -  Patients with CNS and/or leptomeningeal disease metastases

          -  Presence or history of thromboembolic or cerebrovascular events

          -  Impaired cardiac function or clinically significant cardiac disease

          -  Malabsorption syndrome or uncontrolled gastrointestinal toxicities

          -  Patients known to be HIV- or HBV- or HCV- positive

          -  Patients with acute or chronic uncontrolled infection

          -  Patients who have undergone surgery with general anesthesia for any cause within 28
             days prior to the first dose of study drug

          -  Patients who have been receiving anticoagulant therapy

          -  Receipt of any hematopoietic colony stimulating factor or blood transfusion within 14
             days prior to the first dose of study drug

          -  Patients who have been administering concomitant medication which may prolong the QTc
             interval

          -  Patients with interstitial pneumonia or pulmonary fibrosis proven on a chest CT scan

          -  Patients with a large volume of ascitic and/or pleural fluid which requires drainage

          -  Patients with any bone fractures

          -  Deemed otherwise unsuitable by the investigator

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00251589 (phase 1/phase 2, status: terminated)
Conditions: carcinoma, non-small-cell lung
ICD codes: D02.20, D02.21, D02.22
Drugs: vorinostat, vorinostat, vorinostat, vorinostat, erlotinib
SMILES: ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1, ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1, ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1, ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1, COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2
Reason stopped: 
    this trial is being closed based on lack of substantive efficacy, slow accrual and overall
    tolerance in patients treated to date.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Males and females 18 years of age and older with a confirmed diagnosis of
             non-small-cell lung cancer (NSCLC) who have failed at least one prior treatment for
             NSCLC.

          -  Patients must have proven disease by CT scan or MRI.

          -  Patients must be at least 4 weeks from any chemotherapy for cancer or from any
             surgeries or from any treatment using an investigational drug.

          -  Patients must be 2 weeks out from radiation therapy.

          -  At screening the patient must have normal lab results and can not be pregnant.

          -  Women and men must agree to practice adequate birth control during the study.

          -  Patient has the ability to understand and sign the consent form.

        Exclusion Criteria:

          -  Patient had prior treatment with vorinostat or erlotinib.

          -  Patient has any of the following conditions: active infections including hepatitis B
             or C, unstable brain metastases, swallowing difficulties, heart problems, significant
             eye abnormalities, drug or alcohol abuse, mental illness or pregnancy.
Clinical trial NCT01526577 (phase 1, status: completed)
Conditions: acute coronary syndrome
ICD codes: I24.0
Drugs: lc23-1306, placebo, ticagrelor
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@](N1CCC2=C(C1)C=CS2)(C(=O)OC)C1=CC=CC=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          1. Healthy male subjects between the ages of 20 and 50 years at screening

          2. Subjects with Body Mass Index (BMI) between 18.0 (inclusive) and 27.0 kg/m2
             (exclusive); and a total body weight between 55 kg (inclusive) and 90 kg (exclusive).
             BMI (kg/m2) = body weight (kg)/ {height (m)}2.

          3. Subject is informed of the investigational nature of this study and voluntarily agrees
             to participate in this study and signs an Institutional Review Board (IRB) - approved
             informed consent prior to performing any of the screening procedures.

          4. Findings within the range of clinical acceptability in medical history and physical
             examination, and laboratory results within the laboratory reference ranges for the
             relevant laboratory tests
Clinical trial NCT00363168 (phase 1, status: completed)
Conditions: choroidal neovascularization
ICD codes: H44.2A1, H44.2A2, H44.2A3, H44.2A9, H35.3231, H35.3232, H35.3211
Drugs: ranibizumab, ranibizumab
SMILES: CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O, CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O
Eligibility criteria:

        Inclusion Criteria:

        Subjects will be eligible if the following criteria are met:

          -  Ability to provide written informed consent and comply with study assessments for the
             full duration of the study.

          -  Predominantly hemorrhagic subfoveal CNV (at least 50% of the lesion composed of
             hemorrhage) from age-related macular degeneration (AMD) resulting in visual acuity of
             20/40 or worse.

          -  Age greater than 50 years.

          -  Participant must have media clear enough to permit fundus photography, fluorescein
             angiography, and optical coherence tomography.

        Exclusion Criteria:

        Subjects who meet any of the following criteria will be excluded from this study:

          -  Known hypersensitivity to humanized monoclonal antibodies

          -  History (within past 6 months) or evidence of severe cardiac disease (apparent in
             electrocardiogram abnormalities, clinical history of unstable angina, acute coronary
             syndrome, myocardial infarction, revascularization procedure within 6 months prior to
             baseline, atrial or ventricular tachyarrhythmias requiring ongoing treatment).

          -  History of stroke within 6 months of study entry.

          -  Current acute ocular or periocular infection.

          -  Any major surgical procedure within one month of study entry.

          -  Known serious allergies to fluorescein dye.

          -  Previous participation in a clinical trial (for either eye) involving anti-angiogenic
             drugs (pegaptanib, ranibizumab, anecortave acetate, Protein Kinase C inhibitors, etc)
             within last 6 months.

          -  Previous intravitreal drug delivery (e.g., intravitreal corticosteroid injection or
             device implantation) in the study eye within the last 6 months.

          -  History of subfoveal laser treatment in the study eye.

          -  History of other visually-limiting conditions such as optic neuropathy, amblyopia,
             choroidal neovascularization due to causes other than AMD in the study eye.

          -  Ocular inflammation (including trace or above) in the study eye.

          -  Inability to comply with study or follow up procedures.
Clinical trial NCT00453791 (phase 1, status: terminated)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: gw805858, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Men or women of non-child bearing potential, aged between 18 and 60 years of age
             inclusive.

          -  Body weight = 50 kg (110 lbs) for men and = 45 kg for women and Body Mass Index (BMI)
             within the range 19.0-30.0 kg/m2 inclusive.

          -  The subject is a current non-smoker who has not used any tobacco products in the last
             year.

          -  A signed and dated written informed consent is obtained for the subject.

          -  The subject is able to understand and comply with protocol requirements and
             timetables, instructions and protocol-stated restrictions.

          -  If asthmatic, the subject must be a clinically stable asthmatic.

        Exclusion Criteria:

          -  The subject has a history of allergy to ingredients within the inhaler.

          -  The subject has received an investigational drug or participated in any other research
             trial within 30 days, prior to the first dose of current study medication.

          -  The subject has used prescription or non-prescription drugs, including vitamins,
             herbal and dietary supplements (including St John's Wort) within 14 days prior to the
             first dose of study medication.

          -  The subject has an average weekly alcohol intake of greater than 21 units if male or
             14 units if female.

          -  The subject has any history of breathing problems (e.g. history of asthmatic
             symptoms).

          -  The subject is infected with the hepatitis B, hepatitis C, or HIV virus.

          -  The subject has had a respiratory tract infection or worsening of asthma within 4
             weeks of the start of the study.

          -  The subject has a past or present disease, which as judged by the Investigator, may
             affect the outcome of this study.

          -  The subject has a history of life-threatening asthma, defined as an asthma episode
             that required intubation and/or was associated with hypercapnea, respiratory arrest or
             hypoxia seizures.

          -  The subject has taken inhaled, nasal or dermal steroids within 4 weeks or oral
             steroids within 8 weeks of the start of the study.

          -  The subject is unable to abstain from other drugs that may interfere with the conduct
             of the study.

          -  The subject has ongoing rhinitis that requires treatment.